Partial splenectomy in children under 4 years of age with hemoglobinopathy.
OBJECTIVE
The risk of septicemia in postsplenectomy pediatric patients is approximately 2%. This risk is twice as great for children less than 4 years of age. In the first year of life this risk can be 30% or higher. Partial splenectomy is an alternative in patients with hemoglobinopathies. The authors attempt to assess the outcome of pediatric patients less than 4 years of age undergoing partial splenectomy using the Argon beam.


METHODS
In a tertiary care, university affiliated, dedicated children's hospital seven patients underwent partial splenectomy (PS) by the same surgeon from May 1993 to September 1995. The PS performed for trauma was excluded. Included were patients with hemoglobinopathies. Therefore, six patients were evaluated. Follow-up was from 6 months to 2 years. Pre- and postoperative blood transfusions, length of operation, estimated blood loss, length of hospital stay, postoperative complications, perfusion, and function of remnant spleen were evaluated.


RESULTS
Indications for splenectomy included sequestration crisis and hypersplenism. Percent splenectomy ranged from 65% to 75%. Average hospital stay was 6.3 days. Postoperative splenic function, measured by Pitt count and radionuclide spleen scan, was normal. Postoperatively there were no systemic infections, overwhelming postsplenectomy sepsis (OPSS), torsion of the splenic remnant, left upper quadrant fluid collections, or subphrenic abscesses. There were no deaths.


CONCLUSIONS
Partial splenectomy is a safe and effective procedure in children less than 4 years of age with hemoglobinopathies. The procedure as described yields minimal blood loss and retains immune competence. Partial splenectomy greatly reduces, and in some cases eliminates, the need for blood transfusions. PS should be considered the procedure of choice in children less than 4 years of age with sickle cell anemia or beta-thalassemia who require splenectomy.
University of California Davis-East Bay, Oakland, CA 94609, USA.
O
O
Idowu
A
A
Hayes-Jordan
D000367:Age Factors; D001128:Argon / Q000627:therapeutic use; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006453:Hemoglobinopathies / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D007223:Infant; D053685:Laser Therapy; D008297:Male; D013156:Splenectomy / Q000295:instrumentation / Q000379:methods*; D013163:Splenomegaly / Q000209:etiology / Q000601:surgery*; D016896:Treatment Outcome
D001128:Argon